<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657289</url>
  </required_header>
  <id_info>
    <org_study_id>WR42221</org_study_id>
    <nct_id>NCT04657289</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)</brief_title>
  <official_title>A Phase IIIb, Global, Multicenter, Randomized, Visual Assessor-Masked Study Of The Efficacy, Safety, And Pharmacokinetics Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab In Patients With Neovascular Age-Related Macular Degeneration (Velodrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study&#xD;
      designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System&#xD;
      with ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W) compared with every 24 weeks&#xD;
      (Q24W) in patients with neovascular age-related macular degeneration (nAMD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2021</start_date>
  <completion_date type="Anticipated">September 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 21, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 3b</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The BCVA examiner will only conduct refraction and BCVA assessments and will be masked to participant study eye assignment and study visit type.&#xD;
The BCVA examiner will have no access to a participant's BCVA scores from previous visits and will be aware only of the participant's refraction data from previous visits.&#xD;
The BCVA examiner may provide no other direct or indirect participant care.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Best-corrected visual acuity (BCVA) score averaged over Weeks 68 and 72, as assessed using the ETDRS chart starting at a distance of 4 meters</measure>
    <time_frame>Baseline to Week 72</time_frame>
    <description>EDTRS = Early Treatment Diabetic Retinopathy Study. A vision score of 20/20 vision is considered normal. A score of 20/200 is considered being legally blind.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BCVA score over time</measure>
    <time_frame>Baseline up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with BCVA score of 69 letters (approximate 20/40 Snellen equivalent) or better averaged over Weeks 68 and 72</measure>
    <time_frame>Baseline to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with BCVA score of 69 letters (approximate 20/40 Snellen equivalent) or better over time</measure>
    <time_frame>Baseline up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with BCVA score of 38 letters (approximate 20/200 Snellen equivalent) or worse averaged over Weeks 68 and 72</measure>
    <time_frame>Baseline to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with BCVA score of 38 letters (approximate 20/200 Snellen equivalent) or worse over time</measure>
    <time_frame>Baseline up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who report preferring ranibizumab 100 mg/mL delivered via the PDS compared with intravitreal treatment, as measured by the PDS Patient Preference Questionnaire (PPPQ) at Week 40</measure>
    <time_frame>At Week 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with bilateral disease who report preferring ranibizumab 100 mg/mL delivered via the PDS compared with intravitreal treatment, as measured by the PPPQ at Week 40</measure>
    <time_frame>At Week 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who lose &lt;10, &lt;5, or gain &gt;= 0 letters in BCVA score from baseline averaged over Weeks 68 and 72</measure>
    <time_frame>Baseline to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who lose &lt;10, &lt;5, or gain &gt;= 0 letters in BCVA score from baseline over time</measure>
    <time_frame>Baseline up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in center point thickness (CPT) up to and including Week 72</measure>
    <time_frame>Baseline up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who do not undergo supplemental treatment with intravitreal ranibizumab 0.5 mg before each refill-exchange procedure</measure>
    <time_frame>Week 16 to Week 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of ocular and systemic (non-ocular) adverse events in Q36W compared with Q24W</measure>
    <time_frame>Baseline up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, severity, and duration of adverse events of special interest, including ocular adverse events of special interest in Q36W compared with Q24W</measure>
    <time_frame>Baseline up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, severity, and duration of ocular adverse events of special interest during the postoperative period (≤ 37 days of initial implantation) and follow-up period (&gt; 37 days after implantation surgery) in all enrolled participants</measure>
    <time_frame>Baseline up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed serum concentration of ranibizumab at specified timepoints</measure>
    <time_frame>Baseline to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent ADAs during the study</measure>
    <time_frame>Baseline to Week 72</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">442</enrollment>
  <condition>Neovascular Age-related Macular Degeneration (nAMD)</condition>
  <arm_group>
    <arm_group_label>Arm A [Q36W] 36-weeks between refill-exchange procedures</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the Q36W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q36W fixed interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B [Q24W] 24-weeks between refill-exchange procedures</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to the Q24W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q24W fixed interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDS Implant filled with 100 mg/mL Ranibizumab</intervention_name>
    <description>Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals&#xD;
Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals</description>
    <arm_group_label>Arm A [Q36W] 36-weeks between refill-exchange procedures</arm_group_label>
    <arm_group_label>Arm B [Q24W] 24-weeks between refill-exchange procedures</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 50 years at time of signing Informed Consent Form&#xD;
&#xD;
          -  Initial diagnosis of nAMD within 9 months prior to the screening visit&#xD;
&#xD;
          -  Previous treatment with at least three anti- vascular endothelial growth factor (VEGF)&#xD;
             intravitreal injections for nAMD per standard of care within 6 months prior to the&#xD;
             screening visit&#xD;
&#xD;
          -  Demonstrated response to prior anti-VEGF intravitreal treatment since diagnosis&#xD;
&#xD;
          -  Availability of historical visual acuity data prior to the first anti-VEGF treatment&#xD;
             for nAMD until the time of study enrollment&#xD;
&#xD;
          -  BCVA of 34 letters (approximate 20/200 Snellen equivalent) or better&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for&#xD;
             AMD in study eye&#xD;
&#xD;
          -  Prior treatment with Visudyne®, external-beam radiation therapy, or transpupillary&#xD;
             thermotherapy in study eye&#xD;
&#xD;
          -  Previous treatment with corticosteroid intravitreal injection, intraocular device&#xD;
             implantation, previous laser (any type) used for AMD treatment in study eye&#xD;
&#xD;
          -  Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the&#xD;
             enrollment visit in study eye&#xD;
&#xD;
          -  Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the&#xD;
             supero-temporal quadrant of the eye that may affect the implantation, subsequent&#xD;
             tissue coverage, and refill-exchange procedure of the PDS implant&#xD;
&#xD;
          -  Prior treatment with brolucizumab (at any time prior to the screening visit) in either&#xD;
             eye&#xD;
&#xD;
          -  Prior participation in a clinical trial involving any anti-VEGF drugs, within 6 months&#xD;
             prior to the enrollment visit in either eye&#xD;
&#xD;
          -  Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is &gt;0.5&#xD;
             disc area at screening in study eye&#xD;
&#xD;
          -  Subfoveal fibrosis or subfoveal atrophy in study eye&#xD;
&#xD;
          -  CNV due to other causes, such as ocular histoplasmosis, trauma, central serous&#xD;
             chorio-retinopathy, or pathologic myopia in either eye&#xD;
&#xD;
          -  Retinal pigment epithelial tear in study eye&#xD;
&#xD;
          -  Any concurrent intraocular condition that would either require surgical intervention&#xD;
             during the study to prevent or treat visual loss that might result from that condition&#xD;
             or affect interpretation of study results in study eye&#xD;
&#xD;
          -  Active intraocular inflammation in study eye&#xD;
&#xD;
          -  History of vitreous hemorrhage in study eye&#xD;
&#xD;
          -  History of rhegmatogenous retinal detachment in study eye&#xD;
&#xD;
          -  History of rhegmatogenous retinal tears or peripheral retinal breaks within 3 months&#xD;
             prior to the enrollment visit in study eye&#xD;
&#xD;
          -  Aphakia or absence of the posterior capsule in study eye&#xD;
&#xD;
          -  Spherical equivalent of the refractive error demonstrating more than 8 diopters of&#xD;
             myopia in study eye&#xD;
&#xD;
          -  Preoperative refractive error that exceeded 8 diopters of myopia, for Participants who&#xD;
             have undergone prior refractive or cataract surgery in study eye&#xD;
&#xD;
          -  Intraocular surgery within 3 months preceding the enrollment visit in study eye&#xD;
&#xD;
          -  Uncontrolled ocular hypertension or glaucoma and any such condition the investigator&#xD;
             determines may require a glaucoma-filtering surgery during a participant's&#xD;
             participation in the study in study eye&#xD;
&#xD;
          -  History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery&#xD;
             in study eye&#xD;
&#xD;
          -  History of corneal transplant in study eye&#xD;
&#xD;
          -  Any history of uveitis requiring treatment in either eye&#xD;
&#xD;
          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either&#xD;
             eye&#xD;
&#xD;
          -  Uncontrolled blood pressure&#xD;
&#xD;
          -  History of stroke within the last 3 months prior to informed consent&#xD;
&#xD;
          -  Atrial fibrillation diagnosed or worsened within the last 3 months prior to informed&#xD;
             consent&#xD;
&#xD;
          -  History of myocardial infarction within the last 3 months prior to informed consent,&#xD;
&#xD;
          -  History of other disease, metabolic dysfunction, or clinical laboratory finding giving&#xD;
             reasonable suspicion of a disease or condition that contraindicates the use of&#xD;
             ranibizumab or placement of the implant and that might affect interpretation of the&#xD;
             results of the study or renders the participant at high risk of treatment&#xD;
             complications in the opinion of the investigator&#xD;
&#xD;
          -  Confirmed active systemic infection&#xD;
&#xD;
          -  Use of any systemic anti-VEGF agents&#xD;
&#xD;
          -  Active cancer within 12 months of enrollment except for appropriately treated&#xD;
             carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with&#xD;
             a Gleason score of &lt;= 6 and a stable prostate-specific antigen for &gt; 12 months&#xD;
&#xD;
          -  Previous participation in any non-ocular disease studies of investigational drugs&#xD;
             within 1 month preceding the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: WR42221 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Oftalmológico Dr. Charles S.A.</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1116</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oftalmos</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1120AAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grupo Laser Vision</name>
      <address>
        <city>Rosario</city>
        <zip>S2000DLA</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eyeclinic Albury Wodonga</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina and Macula Specialists</name>
      <address>
        <city>Hurstville</city>
        <state>New South Wales</state>
        <zip>2220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydney Eye Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydney Retina Clinic and Day Surgery</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre For Eye Research Australia</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Specialists Victoria</name>
      <address>
        <city>Rowville</city>
        <state>Victoria</state>
        <zip>3178</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien; Universitätsklinik für Augenheilkunde und Optometrie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah MC; Ophtalmology</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel Ophthalmologische Klinik</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern Ophthalmologische Klinik</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vista Klinik Ophthalmologische Klinik</name>
      <address>
        <city>Binningen</city>
        <zip>4102</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli Ophthalmologische Klinik</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Israel</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

